Taiwan Bio-medical 'National Team' Enters Japan, Partners with iPark to Expand in Asia-Pacific
A delegation of 16 Taiwanese bio-medical companies led by the MOEA participated in CPHI Japan. ITRI signed an MOU with Shonan Health Innovation Park (iPark Institute) to establish a complementary mechanism for R&D, clinical trials, and manufacturing, facilitating Taiwan's entry into the Japanese and Asia-Pacific markets.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 19:37
- 🔍 Collected: April 22, 2026 at 20:01 (24 min after Published)
- 🤖 AI Analyzed: April 22, 2026 at 22:17 (2h 15m after Collected)
(Central News Agency, Tokyo, 22nd) The Department of Industrial Technology of the Ministry of Economic Affairs led 16 indicator bio-medical companies to form a 'Taiwan Team' to enter the CPHI Japan international pharmaceutical exhibition. ITRI signed a cooperation agreement with Japan's prominent bio-medical cluster 'Shonan Health Innovation Park' (iPark Institute) on the 21st. The collaboration will integrate R&D, clinical, and manufacturing capabilities to establish a complementary mechanism between Taiwan and Japan, accelerating the entry of Taiwanese pharmaceutical companies into the Japanese and Asia-Pacific markets.
Deputy Representative of the Taipei Economic and Cultural Representative Office in Japan, Zhou Xueyou, noted in his opening speech that CPHI Japan is a vital platform for the international pharmaceutical industry, covering active pharmaceutical ingredients, CDMO, and regenerative medicine. This year's Taiwan Pavilion not only showcases the long-term strength of Taiwan's medical and biotechnology industry but also deepens the cooperation in the Taiwan-Japan supply chain.
He stated that Taiwan has listed 'Precision Health' as one of the six core strategic industries since 2021, and further included 'Bio-medical' as one of the 13 strategic industries this year. Combining medical and semiconductor advantages to create a high-value-added health industry chain; Japan also lists 'Innovative Drugs and Advanced Medicine' as a growth focus, showing high policy alignment and broad cooperation space.
Dai Jiancheng, a senior official at the MOEA, stated that the pharmaceutical industry is a cornerstone of national health security. Facing global supply chain restructuring and geopolitical changes, 2026 will be a key turning point for Taiwan's pharmaceutical industry to move from R&D advantages to strategic supply chain positioning.
He pointed out that to strengthen industrial resilience, the MOEA is promoting the 'National Pharmaceutical Resilience Plan' to enhance the independent capacity and supply stability of critical medicines. Using CPHI exhibitions as an important field for international layout, they are adopting a phased 'Japan x World' strategy. First, using Japan as a key entrance for regulatory alignment and market introduction; then using Milan, Italy, as a global manufacturing and supply chain hub to connect with international pharmaceutical companies and CDMO systems, amplifying Taiwan's advantages in manufacturing flexibility and technical integration.
Lu Ruimei, Director of the Biomedical and Medical Device Research Laboratories at ITRI, stated that signing the MOU with iPark Institute will strengthen the cooperation between Taiwanese industries and Japanese companies in innovative drugs and key technology R&D, accelerating international layout. Simultaneously, by integrating the advantages of Taiwan and Japan in clinical and manufacturing fields, it will promote the common development of the pharmaceutical industries of both sides and further strengthen the link with the global pharmaceutical market.
Shonan Health Innovation Park is a major bio-medical innovation cluster in Japan. Its president, Toshio Fujimoto, stated that Taiwan possesses solid R&D capabilities, perfect manufacturing foundations, and rich clinical resources, making it a highly potential partner. The cooperation is expected to accelerate the development and industrialization of innovative drugs.
The Taiwan Pavilion this year covers four major fields, demonstrating complete industrial chain integration power. The Department of Industrial Technology pointed out that during the exhibition, matching sessions are scheduled with 14 Japanese pharmaceutical companies, and visits will be made to indicator companies such as Otsuka Pharmaceutical, FUJIFILM Biotechnologies, and Astellas Pharma, hoping to expand contract manufacturing and technical cooperation opportunities through Taiwan's manufacturing resilience and development efficiency advantages, further deepening the Taiwan-Japan pharmaceutical industry chain link.
Deputy Representative of the Taipei Economic and Cultural Representative Office in Japan, Zhou Xueyou, noted in his opening speech that CPHI Japan is a vital platform for the international pharmaceutical industry, covering active pharmaceutical ingredients, CDMO, and regenerative medicine. This year's Taiwan Pavilion not only showcases the long-term strength of Taiwan's medical and biotechnology industry but also deepens the cooperation in the Taiwan-Japan supply chain.
He stated that Taiwan has listed 'Precision Health' as one of the six core strategic industries since 2021, and further included 'Bio-medical' as one of the 13 strategic industries this year. Combining medical and semiconductor advantages to create a high-value-added health industry chain; Japan also lists 'Innovative Drugs and Advanced Medicine' as a growth focus, showing high policy alignment and broad cooperation space.
Dai Jiancheng, a senior official at the MOEA, stated that the pharmaceutical industry is a cornerstone of national health security. Facing global supply chain restructuring and geopolitical changes, 2026 will be a key turning point for Taiwan's pharmaceutical industry to move from R&D advantages to strategic supply chain positioning.
He pointed out that to strengthen industrial resilience, the MOEA is promoting the 'National Pharmaceutical Resilience Plan' to enhance the independent capacity and supply stability of critical medicines. Using CPHI exhibitions as an important field for international layout, they are adopting a phased 'Japan x World' strategy. First, using Japan as a key entrance for regulatory alignment and market introduction; then using Milan, Italy, as a global manufacturing and supply chain hub to connect with international pharmaceutical companies and CDMO systems, amplifying Taiwan's advantages in manufacturing flexibility and technical integration.
Lu Ruimei, Director of the Biomedical and Medical Device Research Laboratories at ITRI, stated that signing the MOU with iPark Institute will strengthen the cooperation between Taiwanese industries and Japanese companies in innovative drugs and key technology R&D, accelerating international layout. Simultaneously, by integrating the advantages of Taiwan and Japan in clinical and manufacturing fields, it will promote the common development of the pharmaceutical industries of both sides and further strengthen the link with the global pharmaceutical market.
Shonan Health Innovation Park is a major bio-medical innovation cluster in Japan. Its president, Toshio Fujimoto, stated that Taiwan possesses solid R&D capabilities, perfect manufacturing foundations, and rich clinical resources, making it a highly potential partner. The cooperation is expected to accelerate the development and industrialization of innovative drugs.
The Taiwan Pavilion this year covers four major fields, demonstrating complete industrial chain integration power. The Department of Industrial Technology pointed out that during the exhibition, matching sessions are scheduled with 14 Japanese pharmaceutical companies, and visits will be made to indicator companies such as Otsuka Pharmaceutical, FUJIFILM Biotechnologies, and Astellas Pharma, hoping to expand contract manufacturing and technical cooperation opportunities through Taiwan's manufacturing resilience and development efficiency advantages, further deepening the Taiwan-Japan pharmaceutical industry chain link.